Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer

Liu Joyce; Nicum Shibani; Reichardt Peter; Croitoru Kenneth; Illek Beate; Schmidinger Manuela; Rogers Catherine; Whalen Christin; Jayson Gordon C.

首页> 外文期刊>Gynecologic Oncology: An International Journal >Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer

【24h】

Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer

机译：卵巢癌患者VEGF受体TKI治疗后腹泻评估和管理

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Angiogenesis is a proven clinical target for the treatment of advanced epithelial ovarian cancer. Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) offer patients potential new treatment regimens as they can be given as monotherapy, in combination with poly(ADP-ribose) polymerase (PARP) inhibitors, or with and following cytotoxic chemotherapy.

机译：血管生成是治疗晚期上皮性卵巢癌的验证临床目标。血管内皮生长因子受体酪氨酸激酶抑制剂（VEGFR-TKIS）为患者提供潜在的新治疗方案，因为它们可以作为单药治疗，与聚（ADP-核糖）聚合酶（PARP）抑制剂组合，或与细胞毒性化学疗法组合。

著录项

来源
《Gynecologic Oncology: An International Journal》 |2018年第1期|共7页
作者
Liu Joyce; Nicum Shibani; Reichardt Peter; Croitoru Kenneth; Illek Beate; Schmidinger Manuela; Rogers Catherine; Whalen Christin; Jayson Gordon C.;
展开▼
作者单位

Dana Farber Canc Inst Boston MA 02115 USA;

Univ Oxford Dept Oncol Oxford England;

HELIOS Klinikum Berlin Buch Sarkomzentrum Berlin Brandenburg Berlin Germany;

Univ Toronto Mt Sinai Hosp Div Gastroenterol Zane Cohen Ctr Digest Dis Toronto ON Canada;

Childrens Hosp Oakland Res Inst Oakland CA USA;

Med Univ Vienna Div Clin Oncol Dept Med 1 Vienna Austria;

Univ Manchester Christie Hosp 550 Wilmslow Rd Manchester M20 4BX Lancs England;

Dana Farber Canc Inst Boston MA 02115 USA;

Univ Manchester Christie Hosp 550 Wilmslow Rd Manchester M20 4BX Lancs England;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Ovarian cancer; Diarrhea; VEGF receptor tyrosine kinase inhibitor; VEGF; VEGFR; TKI;

机译：卵巢癌;腹泻;VEGF受体酪氨酸激酶抑制剂;VEGF;VEGFR;TKI;

相似文献

外文文献
中文文献
专利

1. Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer [J] . Liu Joyce, Nicum Shibani, Reichardt Peter, Gynecologic Oncology: An International Journal . 2018,第1期

机译：卵巢癌患者VEGF受体TKI治疗后腹泻评估和管理
2. Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium [J] . Guan Jun, Darb-Esfahani Silvia, Richter Rolf, Journal of Cancer Research and Clinical Oncology . 2019,第4期

机译：血管内皮生长因子受体2（VEGFR2）与晚期高级浆液癌患者（HGSOC）的长期存活相关：肿瘤库卵巢癌（TOC）联盟的研究
3. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment [J] . Yu Yuman, Wang Yuehong, Wu Linying, Medicine. . 2021,第5期

机译：表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIS）与贝伐单抗进行高级非鳞状非小细胞肺癌患者的疗效对EGFR-TKI治疗逐渐进展
4. Proteomic comparison of ascites from ovarian cancer patients and ovarian cancer cell lines using HPLC-orbitrap mass spectrometry [C] . Guangyu Zhang, Rodney Rocconi, Michael Finan, ASMS Conference on Mass Spectrometry and Allied Topics . 2008

机译：卵巢癌患者腹水和卵巢癌细胞系的蛋白质组学比较使用HPLC-横谱法质谱法
5. Critical role for retinoid nuclear receptors RAR and RXR in determining the sensitivity of human ovarian cancer cell lines to retinoid treatment [D] . Wu, Shujian 1997

机译：类维生素A核受体RAR和RXR在确定人卵巢癌细胞系对类维生素A治疗的敏感性中的关键作用
6. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations [O] . Jing-Hui Lin, Dong Lin, Ling Xu, 2017

机译：晚期非小细胞肺癌患者临床预后因素与表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）疗效的关联：回顾性评估94例EGFR突变患者
7. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations [O] . Jing-Hui Lin, Dong Lin, Ling Xu, 2016

机译：先进非小细胞肺癌患者临床预后因子和表皮生长因子受体 - 酪氨酸激酶抑制剂（EGFR-TKI）疗效的关联：EGFR突变94例回顾性评估

Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer

摘要

著录项

相似文献

相关主题

期刊订阅